ClinicalTrials.gg
Active, not recruitingNCT02970318Updated Oct 23, 2026Results posted

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

A Phase 3 interventional study of Acalabrutinib (ACP-196) and Rituximab in Chronic Lymphocytic Leukemia, sponsored by Acerta Pharma BV. Active, not recruiting at 157 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
6th of 39
310 · median 61
Started
2017
with 1 other
Phase 3
9 of 39
1 open now
Primary completion
2021-09
later than 4 of 27 live
Registered
8th of 39
by date
Lead sponsor
9 of 39
Acerta Pharma BV

Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 6th largest by enrollment, is one of 2 that started in 2017, is one of 9 in phase 3, reaches primary completion later than 4 of the 27 other live ones, and was the 8th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • CLL
  • BTK
  • Bruton Tyrosine Kinase
  • acalabrutinib
  • ACP-196
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women ≥ 18 years of age.
  2. performance status of 0 to 2.
  3. Diagnosis of CLL that meets published diagnostic criteria (Hallek 2008):

    1. Monoclonal B-cells (either kappa or lambda light chain restricted) that are clonally co-expressing ≥ 1 B-cell marker (CD19, CD20, or CD23) and CD5.
    2. Prolymphocytes may comprise ≤ 55% of blood lymphocytes.
    3. Presence of ≥ 5 x 10\^9 B lymphocytes/L (5000/μL) in the peripheral blood (at any point since initial diagnosis).
  4. Must have documented CD20-positive CLL.
  5. Active disease meeting ≥ 1 of the following IWCLL 2008 criteria for requiring treatment:

    1. Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia ( \< 10 g/dL) and/or thrombocytopenia ( \< 100,000/μL).
    2. Massive (i.e., ≥ 6 cm below the left costal margin), progressive, or symptomatic splenomegaly.
    3. Massive nodes (i.e., ≥ 10 cm in the longest diameter), progressive, or symptomatic lymphadenopathy.
    4. Progressive lymphocytosis with an increase of > 50% over a 2-month period or a LDT of \< 6 months. LDT may be obtained by linear regression extrapolation of ALC obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In subjects with initial blood lymphocyte counts of \< 30 x 10\^9/L (30,000/μL), LDT should not be used as a single parameter to define indication for treatment. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g., infections) should be excluded.
    5. anemia and/or thrombocytopenia that is poorly responsive to standard therapy.
    6. Constitutional symptoms documented in the subject's chart with supportive objective measures, as appropriate, defined as ≥ 1 of the following disease-related symptoms or signs:

    i. Unintentional weight loss ≥ 10% within the previous 6 months before screening.

    ii. Significant fatigue (ECOG performance score 2; inability to work or perform usual activities).

    iii. Fevers higher than 100.5°F or 38.0°C for ≥ 2 weeks before screening without evidence of infection.

    iv. Night sweats for > 1 month before screening without evidence of infection.

  6. Meet the following laboratory parameters:

    1. ≥ 750 cells/μL (0.75 x 10\^9/L), or ≥ 500 cells/μL (0.50 x 10\^9/L) in subjects with documented bone marrow involvement, and independent of growth factor support 7 days before assessment.
    2. Platelet count ≥ 50,000 cells/μL (50 x 10\^9/L), or ≥ 30,000 cells/μL (30 x 10\^9/L) in subjects with documented bone marrow involvement, and without transfusion support 7 days before assessment. Subjects with transfusion-dependent thrombocytopenia are excluded. If an Investigator has chosen bendamustine/rituximab as the Arm B treatment, platelets must be ≥ 75,000 cells/μL (75 x 10\^9/L).
    3. Serum and ALT ≤ 2.0 x .
    4. Total ≤ 1.5 x ULN.
    5. Estimated of ≥ 30 mL/min, calculated using the formula of Cockcroft and Gault [(140-Age) • Mass (kg)/(72 • creatinine mg/dL); multiply by 0.85 if female].
  7. Must have received ≥ 1 prior systemic therapies for CLL. Note: Single-agent or localized radiation are not considered a . If a single-agent anti-CD20 antibody was previously administered, subjects must have received ≥ 2 doses.
  8. Women who are sexually active and can bear children must agree to use highly effective forms of while on the study and for 2 days after the last dose of acalabrutinib, 90 days after the last dose of idelalisib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer. Highly effective forms of contraception are defined in Section 9.2.5.
  9. Men who are sexually active and can beget children must agree to use highly effective forms of contraception during the study and for 90 days after the last dose of idelalisib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer. Highly effective forms of contraception are defined in Section 9.2.5.
  10. Men must agree to refrain from sperm donation during the study and for 90 days after the last dose of idelalisib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer.
  11. Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing capsules without difficulty.
  12. Ability to understand the purpose and risks of the study and provide signed and dated and authorization to use protected health information (in accordance with national and local patient privacy regulations).

Exclusion criteria

Exclusion Criteria:

  1. Known CNS lymphoma or leukemia.
  2. Known prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome.
  3. Uncontrolled AIHA or ITP defined as declining or count secondary to destruction within the screening period or requirement for high doses of (> 20 mg daily of prednisone or equivalent).
  4. Prior exposure to a BCL-2 inhibitor (e.g., venetoclax/ABT-199) or a BCR inhibitor (e.g., BTK inhibitors or PI3K inhibitors). Prior bendamustine is allowed if Investigator's choice for treatment in Arm B is idelalisib with rituximab. Bendamustine retreatment is allowed if the prior response to bendamustine lasted > 24 months.
  5. Received any chemotherapy, external beam radiation therapy, anticancer antibodies, or drug within 30 days before first dose of study drug.
  6. Corticosteroid use > 20 mg daily prednisone equivalent within 1 week before first dose of study drug, except as indicated for other medical conditions such as inhaled steroid for asthma, topical steroid use, or as premedication for administration of study drug or contrast. For example, subjects requiring steroids at daily doses > 20 mg prednisone equivalent systemic exposure daily, or those who are administered steroids for leukemia control or white blood cell count lowering are excluded.
  7. Prior radio- or toxin-conjugated antibody therapy.
  8. Prior stem cell transplant or prior autologous transplant within 6 months of first dose of study drug(s) or presence of graft-vs-host disease or receiving treatment for graft-vs-host disease.
  9. Major surgical procedure within 30 days of first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug.
  10. History of prior except for the following:

    1. Malignancy treated with curative intent and with no evidence of active disease present for more than 2 years before screening and felt to be at low risk for recurrence by treating physician.
    2. Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled nonmelanomatous skin cancer.
    3. Adequately treated carcinoma in situ without current evidence of disease.
  11. Significant cardiovascular disease such as uncontrolled or untreated symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the Functional Classification, or > 480 msec (calculated using Fridericia's formula: QT/RR\^0.33) at screening. Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll on study.
  12. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach, or extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
  13. Received a within 28 days of first dose of study drug.
  14. Known history of infection with or any uncontrolled active systemic infection (e.g., bacterial, viral, or fungal). For study sites in Germany: active infection with human immunodeficiency virus (seropositivity for HIV-1 or HIV-2 antibodies, and if positive, reactivity against the HIV-specific p24 antigen).
  15. Active CMV infection (active viremia as evidenced by positive polymerase chain reaction [PCR] result for CMV DNA).
  16. Serologic status reflecting active or C infection.

    1. Subjects who are anti-HBc positive and who are surface antigen negative will need to have a negative PCR result before randomization. Those who are HbsAg-positive or hepatitis B PCR positive will be excluded.
    2. Subjects who are antibody positive will need to have a negative PCR result before randomization. Those who are hepatitis C PCR positive will be excluded.
  17. Ongoing, drug-induced liver injury, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, ongoing extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension.
  18. History of or ongoing drug-induced pneumonitis.
  19. History of serious allergic reactions including anaphylaxis and toxic epidermal necrolysis.
  20. History of stroke or intracranial hemorrhage within 6 months before first dose of study drug.
  21. History of bleeding diathesis (e.g., hemophilia, von Willebrand disease).
  22. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within 7 days of first dose of study drug.
  23. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening.
  24. Requires treatment with a strong inhibitor/inducer.
  25. Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving proton-pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study.
  26. Breast feeding or pregnant.
  27. Concurrent participation in another therapeutic clinical trial.
  28. /INR or aPTT (in the absence of a Lupus anticoagulant) > 2.0 x . Exception: Subjects receiving warfarin are excluded, however, those receiving other anticoagulant therapy who have a higher INR/aPTT may be permitted to enroll to this study after discussion with the medical monitor.
  29. History of confirmed progressive multifocal leukoencephalopathy (PML)
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
310 participants (actual)

Study arms

  • Experimental
    Acalabrutinib (ACP-196)

    Acalabrutinib (ACP-196) Monotherapy

    Drug: Acalabrutinib (ACP-196)

  • Active comparator
    Rituximab Plus Idelalisib or Bendamustine

    Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine

    Drug: Rituximab · Drug: Idelalisib · Drug: Bendamustine

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment

    To evaluate the efficacy of acalabrutinib monotherapy (Arm A) compared with idelalisib/rituximab or bendamustine/rituximab (Arm B) based on Independent Review Committee (IRC) assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Hallek 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson 2012) hereafter referred to as IWCLL 2008 criteria in subjects with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). As planned and reported in the interim clinical study report (dated 17 July 2019), because the study did cross the boundary at interim analysis. IRC assessments were discontinued after the interim analysis. All IRC-related efficacy analyses in this clinical study report were based on the interim analysis data cutoff date of 15 January 2019. All other efficacy analyses were based on the final analysis data cutoff date of 03 September 2021.

    Time frame: IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up

Secondary outcomes

  1. Progression-free Survival (PFS) Per Investigator Assessment

    PFS per investigator assessment based on the final analysis data cutoff date of 03 September 2021.

    Time frame: From randomization date to date of disease progression or death due to any cause or data cutoff date on 03Sep2021, whichever came first, regardless of use of subsequent anticancer therapy, until 53 months of follow-up.

  2. IRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis

    IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR)

    Time frame: IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up

  3. Investigator Assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 03 September 2021

    IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR)

    Time frame: Investigator assessments were done from randomization date until date of death or date of exit from study or data cut off date on 03Sep2021, whichever came first, up to 53 months of follow-up.

  4. Overall Survival (OS)

    Overall Survival (OS) was based on data cutoff date of 03Sep2021

    Time frame: From randomization date to date of death due to any cause, or date of study discontinuation, or date of data cutoff on 03Sep2021, whichever came first until 54 months of follow-up.

  5. Duration of Response (DOR) Per Independent Review Committee (IRC) Assessment Based on 15 January 2019 Data Cutoff From Interim Analysis.

    Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause.

    Time frame: IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up

  6. Duration of Response (DOR) Per Investigator Assessment Based on 03 September 2021 Data Cutoff

    Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause.

    Time frame: Investigator assessments were done from randomization date until date of death or study discontinuation or data cutoff date on 03Sep2021, whichever came first up to 53 months of follow-up.

  7. Time to Next Treatment (TTNT) Based on 03 September 2021 Data Cutoff

    Time to Next Treatment (TTNT) is defined as the time from date of randomization to date of institution of non-protocol-specified treatment for CLL (or first dose date of acalabrutinib for Arm B subjects crossing over to receive acalabrutinib) or death due to any cause, whichever comes first.

    Time frame: From randomization date to start of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause or study discontinuation or data cutoff date on 03Sep2021,, whichever came first up to 53 months of follow-up.

07

Results

Posted Jun 29, 2023

Participant flow

A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia. A total of 310 subjects met the eligibility criteria and were randomized to the acalabrutinib arm (N = 155) and IR/BR arm (N = 155). All but 3 subjects (1 randomized to acalabrutinib and 2 randomized to IR/BR) received study treatment.

Overall for Arm A & Main for Arm B
Participant flow — Overall for Arm A & Main for Arm B
MilestoneArm A- Acala 100 mg BID- Overall Study PeriodArm B: Investigator Choice (IR or BR)-Main Study PeriodArm B- Inv Choice of IR Crossed Over to Arm A- Acala. 100 mg BIDArm B- Inv. Choice of BR Crossed Over to Arm A- Acala. 100 mg BID
Started15515500
Arm b treatment= idelalisib plus rituximab011900
Arm b treatment = bendamustine plus rituximab03600
Completed0100
Completed992600
Completed992700
Not completed5612800
Withdrew: Lost to follow-up2100
Withdrew: Withdrawal by subject131400
Withdrew: Death413300
Withdrew: Arm b crossed over to arm a acala 100 mg monotherapy08000
ArmB: Inv.Choice Crossed Over to Acala
Participant flow — ArmB: Inv.Choice Crossed Over to Acala
MilestoneArm A- Acala 100 mg BID- Overall Study PeriodArm B: Investigator Choice (IR or BR)-Main Study PeriodArm B- Inv Choice of IR Crossed Over to Arm A- Acala. 100 mg BIDArm B- Inv. Choice of BR Crossed Over to Arm A- Acala. 100 mg BID
Started006317
Completed004214
Not completed00213
Withdrew: Lost to follow-up0020
Withdrew: Withdrawal by subject0011
Withdrew: Death00182

Outcome measures

PrimaryProgression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment

To evaluate the efficacy of acalabrutinib monotherapy (Arm A) compared with idelalisib/rituximab or bendamustine/rituximab (Arm B) based on Independent Review Committee (IRC) assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Hallek 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson 2012) hereafter referred to as IWCLL 2008 criteria in subjects with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). As planned and reported in the interim clinical study report (dated 17 July 2019), because the study did cross the boundary at interim analysis. IRC assessments were discontinued after the interim analysis. All IRC-related efficacy analyses in this clinical study report were based on the interim analysis data cutoff date of 15 January 2019. All other efficacy analyses were based on the final analysis data cutoff date of 03 September 2021.

Time frame:
IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Reported as:
Median · Months
Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment
MonthsArm A: Acalabrutinib MonotherapyArm B: Investigators Choice
Progression-free Survival (PFS) Per Independent Review Committee (IRC) AssessmentNA (NA to NA)16.5 (14.0 to 17.1)
Statistical analysis
  • Arm A: Acalabrutinib Monotherapy vs Arm B: Investigators Choice · Log Rank · p = <0.0001 (Stratified by randomization stratification factors as recorded in IXRS, i.e., presence of del17p (Yes/No), ECOG (0-1/2), # of prior therapies (1-3/4+).) · Hazard ratio (hr): 0.31 · 95% CI 0.20 to 0.49Cox Proportional Hazard Model (Arm A vs. Arm B) stratified by factors as recorded in IXRS, i.e., presence of del17p (Yes/No), ECOG (0-1/2), # of prior therapies (1-3/4+).
SecondaryProgression-free Survival (PFS) Per Investigator Assessment

PFS per investigator assessment based on the final analysis data cutoff date of 03 September 2021.

Time frame:
From randomization date to date of disease progression or death due to any cause or data cutoff date on 03Sep2021, whichever came first, regardless of use of subsequent anticancer therapy, until 53 months of follow-up.
Reported as:
Median · Months
Progression-free Survival (PFS) Per Investigator Assessment
MonthsArm A: Acalabrutinib MonotherapyArm B: Investigator's Choice
Progression-free Survival (PFS) Per Investigator AssessmentNA (45.8 to NA)16.8 (14.1 to 22.5)
Statistical analysis
  • Arm A: Acalabrutinib Monotherapy vs Arm B: Investigator's Choice · Log Rank · p = <0.0001 (Stratified by randomization stratification factors as recorded in IXRS, i.e., presence of del17p (Yes/No), ECOG (0-1/2), # of prior therapies (1-3/4+).) · Hazard ratio (hr): 0.28 · 95% CI 0.20 to 0.38Cox Proportional Hazard Model (Arm A vs. Arm B) stratified by factors as recorded in IXRS, i.e., presence of del17p (Yes/No), ECOG (0-1/2), # of prior therapies (1-3/4+).
SecondaryIRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis

IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR)

Time frame:
IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Reported as:
Count of participants · Participants
IRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis
ParticipantsArm A: Acalabrutinib MonotherapyArm B: Investigator's Choice
IRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis126117
Statistical analysis
  • Arm A: Acalabrutinib Monotherapy vs Arm B: Investigator's Choice · Cochran-Mantel-Haenszel · p = 0.2248 · Risk difference (rd): 5.8 · 95% CI -3.3 to 14.9Risk difference (% Arm A - Arm B) based on Cochran-Mantel-Haenszel test with adjustment for randomization stratification factors as recorded in IXRS.
SecondaryInvestigator Assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 03 September 2021

IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR)

Time frame:
Investigator assessments were done from randomization date until date of death or date of exit from study or data cut off date on 03Sep2021, whichever came first, up to 53 months of follow-up.
Reported as:
Count of participants · Participants
Investigator Assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 03 September 2021
ParticipantsArm A: Acalabrutinib MonotherapyArm B: Investigator's Choice
Investigator Assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 03 September 2021128130
Statistical analysis
  • Arm A: Acalabrutinib Monotherapy vs Arm B: Investigator's Choice · Cochran-Mantel-Haenszel · p = 0.7340 · Risk difference (rd): -1.3 · 95% CI -9.6 to 7.0Risk difference (% Arm A - Arm B) based on Cochran-Mantel-Haenszel test with adjustment for randomization stratification factors as recorded in IXRS.
SecondaryOverall Survival (OS)

Overall Survival (OS) was based on data cutoff date of 03Sep2021

Time frame:
From randomization date to date of death due to any cause, or date of study discontinuation, or date of data cutoff on 03Sep2021, whichever came first until 54 months of follow-up.
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm A: Acalabrutinib MonotherapyArm B: Investigator's Choice
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Arm A: Acalabrutinib Monotherapy vs Arm B: Investigator's Choice · Log Rank · p = 0.0783 · Hazard ratio (hr): 0.69 · 95% CI 0.46 to 1.04Cox proportional hazard analysis stratified (Arm A vs. Arm B) by factors recorded in IXRS data including presence of deletion 17 p (yes / no), ECOG (0-1/2), # of prior therapies (1-3/4+).
SecondaryDuration of Response (DOR) Per Independent Review Committee (IRC) Assessment Based on 15 January 2019 Data Cutoff From Interim Analysis.

Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause.

Time frame:
IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Reported as:
Median · Months
Duration of Response (DOR) Per Independent Review Committee (IRC) Assessment Based on 15 January 2019 Data Cutoff From Interim Analysis.
MonthsArm A: Acalabrutinib MonotherapyArm B: Investigator's Choice
Duration of Response (DOR) Per Independent Review Committee (IRC) Assessment Based on 15 January 2019 Data Cutoff From Interim Analysis.NA (NA to NA)13.6 (11.9 to NA)
Statistical analysis
  • Arm A: Acalabrutinib Monotherapy vs Arm B: Investigator's Choice · Log Rank · p = <0.0001 (Log Rank Test stratified by factors as recorded in IXRS, i.e., presence of del17p (Yes/No), ECOG (0-1/2), # of prior therapies (1-3/4+).) · Hazard ratio (hr): 0.33 · 95% CI 0.19 to 0.59Cox Proportional Hazard Model (Arm A vs. Arm B) stratified by factors as recorded in IXRS, i.e., presence of del17p (Yes/No), ECOG (0-1/2), # of prior therapies (1-3/4+).
SecondaryDuration of Response (DOR) Per Investigator Assessment Based on 03 September 2021 Data Cutoff

Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause.

Time frame:
Investigator assessments were done from randomization date until date of death or study discontinuation or data cutoff date on 03Sep2021, whichever came first up to 53 months of follow-up.
Reported as:
Median · Months
Duration of Response (DOR) Per Investigator Assessment Based on 03 September 2021 Data Cutoff
MonthsArm A: Acalabrutinib MonotherapyArm B: Investigator's Choice
Duration of Response (DOR) Per Investigator Assessment Based on 03 September 2021 Data CutoffNA (41.5 to NA)18.3 (11.9 to 21.7)
Statistical analysis
  • Arm A: Acalabrutinib Monotherapy vs Arm B: Investigator's Choice · Log Rank · p = <0.0001 (Log Rank Test stratified by factors as recorded in IXRS, i.e., presence of del17p (Yes/No), ECOG (0-1/2), # of prior therapies (1-3/4+).) · Hazard ratio (hr): 0.23 · 95% CI 0.16 to 0.33Cox Proportional Hazard Model (Arm A vs. Arm B) stratified by factors as recorded in IXRS, i.e., presence of del17p (Yes/No), ECOG (0-1/2), # of prior therapies (1-3/4+).
SecondaryTime to Next Treatment (TTNT) Based on 03 September 2021 Data Cutoff

Time to Next Treatment (TTNT) is defined as the time from date of randomization to date of institution of non-protocol-specified treatment for CLL (or first dose date of acalabrutinib for Arm B subjects crossing over to receive acalabrutinib) or death due to any cause, whichever comes first.

Time frame:
From randomization date to start of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause or study discontinuation or data cutoff date on 03Sep2021,, whichever came first up to 53 months of follow-up.
Reported as:
Median · Months
Time to Next Treatment (TTNT) Based on 03 September 2021 Data Cutoff
MonthsArm A: Acalabrutinib MonotherapyArm B: Investigator's Choice
Time to Next Treatment (TTNT) Based on 03 September 2021 Data CutoffNA (46.9 to NA)22.5 (17.5 to 25.9)
Statistical analysis
  • Arm A: Acalabrutinib Monotherapy vs Arm B: Investigator's Choice · Log Rank · p = <0.0001 (Log Rank Test stratified by factors as recorded in IXRS, i.e., presence of del17p (Yes/No), ECOG (0-1/2), # of prior therapies (1-3/4+).) · Hazard ratio (hr): 0.29 · 95% CI 0.21 to 0.40Cox Proportional Hazard Model (Arm A vs. Arm B) stratified by factors as recorded in IXRS, i.e., presence of del17p (Yes/No), ECOG (0-1/2), # of prior therapies (1-3/4+).

Adverse events

Collected over All adverse events were reported from randomization date until 30 days after the last dose of study drug or the start of new anticancer therapy (whichever comes first) up to 54 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A- Acala. 100 mg BID41/155 (26.5%)70/154 (45.5%)149/154 (96.8%)
Arm B: Investigator Choice (IR or BR)-Main Study Period33/155 (21.3%)86/153 (56.2%)145/153 (94.8%)
Arm B Cross Over20/80 (25%)31/80 (38.8%)73/80 (91.3%)
Most frequent serious events
Showing 10 of 146
Most frequent serious events
EventArm A- Acala. 100 mg BIDArm B: Investigator Choice (IR or BR)-Main Study PeriodArm B Cross Over
DiarrhoeaGastrointestinal disorders2/15419/1531/80
PneumoniaInfections and infestations14/15413/1537/80
PyrexiaGeneral disorders5/1549/1531/80
AnaemiaBlood and lymphatic system disorders2/1545/1534/80
Covid-19 pneumoniaInfections and infestations6/1541/1530/80
Pneumonia pneumococcalInfections and infestations0/1544/1530/80
EnterocolitisGastrointestinal disorders1/1544/1530/80
Covid-19Infections and infestations3/1541/1532/80
Septic shockInfections and infestations0/1541/1532/80
Acute kidney injuryRenal and urinary disorders0/1541/1532/80
Most frequent other events
Showing 10 of 581
Most frequent other events
EventArm A- Acala. 100 mg BIDArm B: Investigator Choice (IR or BR)-Main Study PeriodArm B Cross Over
NeutropeniaBlood and lymphatic system disorders37/15467/15316/80
DiarrhoeaGastrointestinal disorders32/15464/15310/80
HeadacheNervous system disorders36/1547/15312/80
Upper respiratory tract infectionInfections and infestations31/15424/1535/80
AnaemiaBlood and lymphatic system disorders27/15417/15316/80
PneumoniaInfections and infestations30/15419/1539/80
PyrexiaGeneral disorders25/15429/15310/80
CoughRespiratory, thoracic and mediastinal disorders27/15420/1538/80
ArthralgiaMusculoskeletal and connective tissue disorders20/1548/15314/80
NauseaGastrointestinal disorders13/15424/1535/80

Baseline characteristics

Analysis was performed on Intent-to-Treat (ITT) population, which included all randomized participants grouped according to assigned treatment.

Age, Customized
Age, Customized(Participants)Arm A- Acala. 100 mg BIDArm B: Investigator Choice (IR or BR)-Main Study PeriodTotal
Age < 65 Years5857115
Age >=65 years9798195
Sex: Female, Male
Sex: Female, Male(Participants)Arm A- Acala. 100 mg BIDArm B: Investigator Choice (IR or BR)-Main Study PeriodTotal
Female4755102
Male108100208
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A- Acala. 100 mg BIDArm B: Investigator Choice (IR or BR)-Main Study PeriodTotal
Hispanic or Latino268
Not Hispanic or Latino147129276
Unknown or Not Reported62026
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A- Acala. 100 mg BIDArm B: Investigator Choice (IR or BR)-Main Study PeriodTotal
American Indian or Alaska Native000
Asian7714
Native Hawaiian or Other Pacific Islander011
Black or African American000
White145141286
More than one race000
Unknown or Not Reported369
Region of Enrollment
Region of Enrollment(Participants)Arm A- Acala. 100 mg BIDArm B: Investigator Choice (IR or BR)-Main Study PeriodTotal
North America8917
Australia6612
New Zealand314
Europe131132263
Taiwan, Province Of China101
Hong Kong011
Korea, Republic Of347
Singapore325
08

Study locations

157 sites
  • Research Site
    Chandler, Arizona 85224, United States
  • Research Site
    Oxnard, California 93030, United States
  • Research Site
    Athens, Georgia 30607, United States
  • Research Site
    Joliet, Illinois 60435, United States
  • Research Site
    Cedar Rapids, Iowa 52403, United States
  • Research Site
    Mount Sterling, Kentucky 40353, United States
  • Research Site
    Saint Cloud, Minnesota 56303, United States
  • Research Site
    Lincoln, Nebraska 68506, United States
  • Research Site
    Brick, New Jersey 08724, United States
  • Research Site
    Nyack, New York 10960, United States
  • Research Site
    Canton, Ohio 44719, United States
  • Research Site
    Fort Sam Houston, Texas 78234, United States
  • Research Site
    Round Rock, Texas 78665, United States
  • Research Site
    Adelaide, 5000, Australia
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    Frankston, 3199, Australia
  • Research Site
    Geelong, 3220, Australia
  • Research Site
    Gosford, 2250, Australia
  • Research Site
    Hobart, 7000, Australia
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    Murdoch, 6150, Australia
  • Research Site
    Nedlands, 6009, Australia
  • Research Site
    South Brisbane, 4101, Australia
  • Research Site
    Woodville, 5011, Australia
  • Research Site
    Linz, 4010, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Vienna, 1130, Austria
  • Research Site
    Vienna, 1160, Austria
  • Research Site
    Wels, 4600, Austria
  • Research Site
    Antwerp, 2060, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Roeselare, 8900, Belgium
  • Research Site
    Yvoir, 5530, Belgium
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Stara Zagora, 6000, Bulgaria
  • Research Site
    Vratsa, 3000, Bulgaria
  • Research Site
    Barrie, Ontario L4M 6M2, Canada
  • Research Site
    Calgary, T2N 2T9, Canada
  • Research Site
    Montreal, H3T 1E2, Canada
  • Research Site
    Ottawa, K1H 8L6, Canada
  • Research Site
    Regina, S4T 7T1, Canada
  • Research Site
    Saint John, E2L 4L2, Canada
  • Research Site
    Toronto, M4N 3M5, Canada
  • Research Site
    Toronto, M5G 2M9, Canada
  • Research Site
    Zadar, 23 000, Croatia
  • Research Site
    Zagreb, 10 000, Croatia
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Nový Hradec Králové, 500 05, Czechia
  • Research Site
    Olomouc, 779 00, Czechia
  • Research Site
    Ostrava Poruba, 708 52, Czechia
  • Research Site
    Plzen - Lochotin, 304 60, Czechia
  • Research Site
    Prague, 100 34, Czechia
  • Research Site
    Bordeaux, 33076, FR, France
  • Research Site
    Brest, 29609, France
  • Research Site
    Montpellier, 34295, France
  • Research Site
    Nantes, 44093, France
  • Research Site
    Paris, 75010, France
  • Research Site
    Paris, 75651, France
  • Research Site
    Perpignan, 66000, France
  • Research Site
    Provence Alpes Cote D'Azur, 13273, France
  • Research Site
    Rennes, 35000, France
  • Research Site
    Rouen, 76038, France
  • Research Site
    Aschaffenburg, 63739, Germany
  • Research Site
    Dresden, 1307, Germany
  • Research Site
    Mutlangen, 73557, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Hong Kong, 150001, Hong Kong
  • Research Site
    Pok Fu Lam, Hong Kong
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Gyula, 5700, Hungary
  • Research Site
    Kaposvár, 7400, Hungary
  • Research Site
    Ashkelon, 7830604, Israel
  • Research Site
    Haifa, 34362, Israel
  • Research Site
    Jerusalem, 9112001, Israel
  • Research Site
    Kfar Saba, 4428164, Israel
  • Research Site
    Nahariya, 22100, Israel
  • Research Site
    Petah Tikvah, 49102, Israel
  • Research Site
    Aviano, 33081, Italy
  • Research Site
    Bergamo, 24127, Italy
  • Research Site
    Brescia, 25123, Italy
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Genova, 16126, Italy
  • Research Site
    Genova, 16132, Italy
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Milan, 20162, Italy
  • Research Site
    Modena, 41100, Italy
  • Research Site
    Addington, 8011, New Zealand
  • Research Site
    Dunedin, 9016, New Zealand
  • Research Site
    Palmerston North, 4442, New Zealand
  • Research Site
    Tauranga, 3112, New Zealand
  • Research Site
    Bialystok, 15-276, Poland
  • Research Site
    Bydgoszcz, 85-168, Poland
  • Research Site
    Gdansk, 80-129, Poland
  • Research Site
    Krakow, 30-727, Poland
  • Research Site
    Lodz, 93-510, Poland
  • Research Site
    Lublin, 20-081, Poland

Showing the first 100 of 157 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Eek D, Ivanescu C, Corredoira L, Meyers O, Cella D. Content validity and psychometric evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue scale in patients with chronic lymphocytic leukemia. J Patient Rep Outcomes. 2021 Mar 11;5(1):27. doi: 10.1186/s41687-021-00294-1. PubMed 33709202 ↗
  • Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, Kaplan P, Kraychok I, Illes A, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery E, Lee JH, Liang W, Patel P, Quah C, Jurczak W. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2020 Sep 1;38(25):2849-2861. doi: 10.1200/JCO.19.03355. Epub 2020 May 27. PubMed 32459600 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Sep 2021, 55 months.

Results were first posted in Jun 2023, 1 year 9 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 55 months is close to that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2016
First posted
Nov 22, 2016
StartActual
Feb 2, 2017
Primary completionActual
Sep 3, 2021
CompletionEst.
Oct 1, 2027
Results first posted
Jun 29, 2023
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02970318
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
Nov 22, 2016
Start date
Feb 2, 2017
Primary completion
Sep 3, 2021
Completion
Oct 1, 2027 (estimated)
Results posted
Jun 29, 2023
Last update
Oct 23, 2026

Study contacts

Acerta Clinical Trials
study director · 1-888-292-9613; acertamc@dlss.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion